GC101 / GeneCradle - LARVOL DELTA

Recent Advances in Tumor-Infiltrating Lymphocyte Therapy for Melanoma. (PubMed, Curr Treat Options Oncol) - "We then review current clinical evidence for conventional TIL products, including lifileucel, TM001, LM103, HS-IT101, and GC101, highlighting their efficacy and safety profiles...In addition, advances in genetically engineered TILs, such as OBX-115, KSQ-001EX, and IOV-4001, are reviewed...Challenges and future directions of TIL therapy in melanoma are also discussed. Overall, TIL therapy constitutes a rapidly evolving and clinically potent treatment modality for melanoma."

Biomarker • IO biomarker • Journal • Review • Tumor-infiltrating lymphocyte • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor • IL2

Single-dose GC101 gene therapy for spinal muscular atrophy types II and III: an open-label single-arm study. (PubMed, World J Pediatr) - "QUICK TAKE."

Journal • Gene Therapies • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: GeneCradle Inc | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Gene Therapies • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases • SMN1 • SMN2

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients (clinicaltrials.gov) - P1/2 | N=33 | Active, not recruiting | Sponsor: GeneCradle Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Gene Therapies • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases • SMN1

Innovative Intrathecal AAV9-mediated Gene Therapy for Spinal Muscular Atrophy: Phase I/II Safety and Efficacy Topline Results (ASGCT 2025) - "GC101, an intrathecal AAV9-mediated gene therapy, is well-tolerated and shows promising efficacy in Type 2 SMA patients. Patients previously treated with Nusinersen and/or Risdiplam can safely benefit from GC101. These results support GC101's ongoing development as a potential Type 2 SMA treatment, with further studies needed to assess long-term safety and efficacy."

Clinical • Gene therapy • P1/2 data • Gene Therapies • Genetic Disorders • Infectious Disease • Movement Disorders • Muscular Atrophy • Pediatrics • Rare Diseases • Respiratory Diseases • SMA4 • SMN1

Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III (clinicaltrials.gov) - P3 | N=50 | Recruiting | Sponsor: GeneCradle Inc

New P3 trial • Gene Therapies • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases

Treatment of SMA type 1 infants using a single-dose AAV9-mediated gene therapy via intrathecal injection of GC101: An open-label, single-arm study. (PubMed, Chin Med J (Engl)) - No abstract available

Gene therapy • Journal • Gene Therapies

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients (clinicaltrials.gov) - P1/2 | N=21 | Recruiting | Sponsor: GeneCradle Inc

Gene therapy • New P1/2 trial • Gene Therapies • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients (clinicaltrials.gov) - P1/2 | N=33 | Recruiting | Sponsor: GeneCradle Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Gene therapy • Gene Therapies • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients (clinicaltrials.gov) - P1/2 | N=33 | Not yet recruiting | Sponsor: GeneCradle Inc

Gene therapy • New P1/2 trial • Gene Therapies • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: GeneCradle Inc

Gene therapy • New P1/2 trial • Gene Therapies • Genetic Disorders • Movement Disorders • Muscular Atrophy • Rare Diseases